All 120 volunteers who tested the first phase Covivac vaccine completed their first shot. Six people got a second shot.
These six people were also the first group to get an injection on March 15. Until now, their health is normal, eligible for the next injection.
Exchange with VnExpress On the afternoon of April 20, Associate Professor, Dr. Vu Dinh Them, Director of the Center for Clinical Trial, Central Institute of Hygiene and Epidemiology, said 120 volunteers aged 18 to 59, divided into 4 groups. injections at doses of 1 mcg, 3 mcg, 10 mcg, and 1 mcg with fortified substances; and the placebo group. It is expected that the entire second phase of phase one will be injected completely by May 15. Two weeks later, the team will have a report evaluating the immunological efficacy of the vaccine before launching the second phase in June.
“If the research process is favorable, it is expected that by the end of 2022 the Covivac vaccine will complete all three phases of clinical trials,” said Associate Professor Thieu.
Up to now, the volunteers who tried the vaccine had only mild reactions such as pain at the injection site, headache, muscle pain … Some reactions were moderate, not recorded cases of severe reactions after injection.
Covivac is the second Covid-19 vaccine from Vietnam in clinical trials. This is Covid-19 vaccine researched and developed by the Institute of Vaccines and Medical Biologicals (IVAC). Vaccines are developed on the egg embryo technology, which is currently applied to some vaccines, such as influenza.
According to IVAC, one dose of Covivac vaccine, which is evaluated to be effective on the British and South African variant according to an overseas screening test, is expected to sell for 60,000 VND. Currently, IVAC’s capacity reaches 6 million doses, but by September, it can be upgraded to 30 million doses a year, capable of supplying Covid-19 vaccine for 60,000 VND per dose to serve people.
The first Covid-19 vaccine in Vietnam to be tested in humans, Nanocovax, produced by Nanogen, has now entered the second stage. Vabiotech is the third Covid-19 vaccine research unit that has not submitted a clinical trial application.